Why the study?
Does a novel covalent antithrombin-heparin (ATH) product improve IIa-TM inhibition and FVa cleavage compared to AT + UFH in vitro?
Population
In vitro models including human umbilical vein endothelial cells (HUVECs) and plastic surfaces
Comparison
Covalent antithrombin-heparin (ATH) product vs Antithrombin (AT) + unfractionated heparin (UFH)
Design
Preclinical
Authors
Loading...
ATH's superior in vitro activity supports further development; leaves open in vivo efficacy and clinical translation.
Does a novel covalent antithrombin-heparin (ATH) product improve IIa-TM inhibition and FVa cleavage compared to AT + UFH in vitro?
The novel covalent antithrombin-heparin product ATH shows enhanced anticoagulant mechanisms by increasing IIa-TM inhibition and accelerating FVa inactivation compared to standard UFH.
Walderveen et al. (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: